Jean L Grem

Jean L Grem

UNVERIFIED PROFILE

Are you Jean L Grem?   Register this Author

Register author
Jean L Grem

Jean L Grem

Publications by authors named "Jean L Grem"

Are you Jean L Grem?   Register this Author

60Publications

-Reads

NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

J Natl Compr Canc Netw 2018 Apr;16(4):359-369

Robert H. Lurie Comprehensive Cancer Center of Northwestern University; UCSF Helen Diller Family Comprehensive Cancer Center; University of Michigan Comprehensive Cancer Center; UC San Diego Moores Cancer Center; City of Hope Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Fox Chase Cancer Center; University of Wisconsin Carbone Cancer Center; Huntsman Cancer Institute at the University of Utah; Fred & Pamela Buffett Cancer Center; Mayo Clinic Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; Moffitt Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Alabama at Birmingham Comprehensive Cancer Center; Stanford Cancer Institute; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; University of Colorado Cancer Center; Dana-Farber/Brigham & Women's Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Roswell Park Comprehensive Cancer Center; Memorial Sloan Kettering Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; The University of Texas MD Anderson Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Duke Cancer Institute; and National Comprehensive Cancer Network.

View Article
April 2018

Pharmacokinetics and Biodistribution of GDC-0449 Loaded Micelles in Normal and Liver Fibrotic Mice.

Pharm Res 2017 03 19;34(3):564-578. Epub 2016 Dec 19.

Department of Pharmaceutical Sciences, University of Nebraska Medical Center (UNMC), 986025 Nebraska Medical Center, Omaha, Nebraska, 68198-6025, USA.

View Article
March 2017

A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.

Cancer 2015 Nov 4;121(21):3862-8. Epub 2015 Aug 4.

Section of Oncology/Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.

View Article
November 2015

Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer.

Br J Clin Pharmacol 2015 Aug 11;80(2):267-75. Epub 2015 Jun 11.

Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA.

View Article
August 2015

Rectal Cancer, Version 2.2015.

J Natl Compr Canc Netw 2015 Jun;13(6):719-28; quiz 728

Robert H. Lurie Comprehensive Cancer Center of Northwestern University; UCSF Helen Diller Family Comprehensive Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Vanderbilt-Ingram Cancer Center; City of Hope Comprehensive Cancer Center; Fox Chase Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Fred & Pamela Buffett Cancer Center; Mayo Clinic Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Alabama at Birmingham Comprehensive Cancer Center; Stanford Cancer Institute; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Colorado Cancer Center; UC San Diego Moores Cancer Center; Roswell Park Cancer Institute; The University of Texas MD Anderson Cancer Center; Massachusetts General Hospital Cancer Center; Memorial Sloan Kettering Cancer Center; Huntsman Cancer Institute at the University of Utah; Moffitt Cancer Center; University of Michigan Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Duke Cancer Institute; and National Comprehensive Cancer Network.

View Article
June 2015

NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors.

Evid Based Complement Alternat Med 2013 27;2013:964592. Epub 2013 Oct 27.

The Cancer Team at Bellin Health, 1580 Commanche Avenue, Green Bay, WI 54313, USA ; National Center for Complementary and Alternative Medicine, NIH, Bethesda, MD, USA.

View Article
November 2013

Sequencing of treatment in advanced unresectable colorectal cancer.

Authors:
Jean L Grem

J Natl Compr Canc Netw 2013 Sep;11 Suppl 4:S28-37

From the Division of Oncology/Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.

View Article
September 2013

Brain metastasis and leptomeningeal carcinomatosis in a patient with cholangiocarcinoma.

Gastrointest Cancer Res 2011 Jul;4(4):144-5

Section of Oncology/Hematology University of Nebraska Medical Center Omaha, NE.

View Article
July 2011

Fatigue and other variables during adjuvant chemotherapy for colon and rectal cancer.

Oncol Nurs Forum 2010 Nov;37(6):E359-69

University of Nebraska Medical Center in Omaha, USA.

View Article
November 2010

Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels.

Br J Pharmacol 2005 Dec;146(7):1027-39

Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK.

View Article
December 2005

Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.

BMC Cancer 2005 Sep 16;5:116. Epub 2005 Sep 16.

Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Naval Medical Center, Bethesda, MD 20889-5105, USA.

View Article
September 2005

Screening for dihydropyrimidine dehydrogenase deficiency.

Authors:
Jean L Grem

Clin Cancer Res 2005 Jul;11(14):5067-8

View Article
July 2005

A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel.

Oncol Rep 2005 Jun;13(6):1145-52

Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute-Navy, National Naval Medical Center, Bethesda, MD 20889-5105, USA.

View Article
June 2005

Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer.

Authors:
Jean L Grem

Semin Oncol 2005 Feb;32(1):120-7

Department of Internal Medicine, Section of Oncology/Hematology, and the Eppley Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.

View Article
February 2005

Severe disabling sensory-motor polyneuropathy during oxaliplatin-based chemotherapy.

Anticancer Drugs 2004 Aug;15(7):733-5

National Cancer Institute-Navy Medical Oncology, Bethesda, MD, USA.

View Article
August 2004

Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry.

J Chromatogr B Analyt Technol Biomed Life Sci 2004 Apr;802(2):263-70

Department of Chemistry, Cleveland State University, 2399 Euclid Ave., Cleveland, OH 44115-2406, USA.

View Article
April 2004

A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin.

Cancer Chemother Pharmacol 2003 Dec 29;52(6):487-96. Epub 2003 Aug 29.

National Cancer Institute-Navy Medical Oncology, National Naval Medical Center, Bethesda, MD 20889, USA.

View Article
December 2003

A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion.

Cancer Chemother Pharmacol 2003 Oct 18;52(4):333-8. Epub 2003 Jun 18.

National Cancer Institute-Navy Medical Oncology, Cancer Therapeutics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, Maryland, USA.

View Article
October 2003

Cardiac toxicity associated with capecitabine therapy.

Acta Oncol 2003 ;42(4):342-4

Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NCI-Navy Medical Oncology, National Naval Medical Center, Bethesda 20889-5105, USA.

View Article
August 2003

Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.

Cancer Chemother Pharmacol 2003 Jul 18;52(1):79-85. Epub 2003 Apr 18.

National Cancer Institute-Navy Medical Oncology, Cancer Therapeutics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, MD 20889-5105, USA.

View Article
July 2003

Hypersensitivity and idiosyncratic reactions to oxaliplatin.

Cancer 2003 May;97(9):2301-7

Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI-Navy Medical Oncology, National Naval Medical Center, Bethesda, Maryland 20889-5105, USA.

View Article
May 2003

Measurement of the anti-cancer agent gemcitabine in human plasma by high-performance liquid chromatography.

J Chromatogr B Analyt Technol Biomed Life Sci 2003 Feb;785(1):65-72

Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute at the National Naval Medical Center, Building 8, Room 5101, 8901 Wisconsin Ave., Bethesda, MD 20889-5105, USA.

View Article
February 2003

Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma.

Authors:
Yan Xu Jean L Grem

J Chromatogr B Analyt Technol Biomed Life Sci 2003 Jan;783(1):273-85

Gastrointestinal Malignancies Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, 20889-5105, Bethesda, MD, USA.

View Article
January 2003

Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.

Clin Cancer Res 2002 May;8(5):1045-50

National Cancer Institute-Navy Medical Oncology, Cancer Therapeutics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, Maryland 20889-5105, USA.

View Article
May 2002

Acute oxaliplatin-induced peripheral nerve hyperexcitability.

J Clin Oncol 2002 Apr;20(7):1767-74

Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article
April 2002

Biochemical and molecular effects of UCN-01 in combination with 5-fluorodeoxyuridine in A431 human epidermoid cancer cells.

Anticancer Drugs 2002 Mar;13(3):259-70

Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute-Navy Medical Oncology, National Naval Medical Center, Bethesda, MD 20889-5105, USA.

View Article
March 2002